- Home
- SGML vs BCRX Comparison
SGML vs BCRX Comparison
Compare SGML & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGML | BCRX |
|---|---|---|
| Founded | 2011 | 1986 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.6B |
| IPO Year | N/A | 1994 |
Fundamental Metrics
Financial Performance| Metric | SGML | BCRX |
|---|---|---|
| Price | $13.24 | $7.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | $13.00 | ★ $20.08 |
| AVG Volume (30 Days) | ★ 4.1M | 3.7M |
| Earning Date | 11-14-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $138,959,151.00 | ★ $599,816,000.00 |
| Revenue This Year | $52.45 | $39.98 |
| Revenue Next Year | $22.13 | $7.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 45.38 |
| 52 Week Low | $4.25 | $6.00 |
| 52 Week High | $14.63 | $11.31 |
Technical Indicators
Market Signals| Indicator | SGML | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 62.25 | 60.75 |
| Support Level | $12.74 | $7.52 |
| Resistance Level | $14.19 | $7.77 |
| Average True Range (ATR) | 1.14 | 0.31 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 71.89 | 88.20 |
Price Performance
Historical ComparisonAbout SGML Sigma Lithium Corporation
Sigma Lithium Corp together with its direct and indirect subsidiaries, is a commercial producer of lithium concentrate. It holds a 100% interest in four mineral properties: Grota do Cirilo, Sao Jose, Santa Clara, and Genipapo, located in the municipalities of Aracuai and Itinga, in the Vale do Jequitinhonha region in the State of Minas Gerais, Brazil.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.